°øÁö»çÇ×

2021³â ´ëÇѾÏÇÐȸ Çмú»ó ¼ö»óÀÚ
ÀÛ¼ºÀÚ
°ü¸®ÀÚ
ÀÛ¼ºÀÏ
2021-07-07
Á¶È¸
3818
2021³â ´ëÇѾÏÇÐȸ Çмú»ó ¼ö»óÀÚ ¸í´Ü
1. Á¦ 13ȸ ´ëÇѾÏÇÐȸ ±âÃÊ¿ì¼ö³í¹®»ó (CRT¿¡ °ÔÀçµÈ ±âÃÊ³í¹®, »ó±Ý °¢ 250¸¸¿ø)
No.ºÐ¾ßÃ¥ÀÓÀúÀÚ/ 1ÀúÀÚ ³í¹®Á¦¸ñ
1 ±âÃÊ ¿Àµµ¿¬(¼­¿ïÀÇ´ë) Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer
Áø¹ÌÈ­(¼­¿ï´ë ¾Ï¿¬±¸¼Ò)
2 ±âÃÊ ÀÌÇý½Â(¼­¿ïÀÇ´ë) PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs
¹ÚÀ¯ÁØ(¼­¿ïÀÇ´ë)
2. Á¦ 1ȸ ´ëÇѾÏÇÐȸ ¿ì¼ö³í¹®»ó (Áß°³ ¹× ÀÓ»óºÎ¹®) : (CRT¿¡ °ÔÀçµÈ ÀÓ»ó ¹× Áß°³ ³í¹®, »ó±Ý °¢ 200¸¸¿ø)
No.ºÐ¾ßÃ¥ÀÓÀúÀÚ/ 1ÀúÀÚ³í¹®Á¦¸ñ
1 ÀÓ»ó ÇÑ¿ø½Ä(¼­¿ïÀÇ´ë)
°ø¼±¿µ(±¹¸³¾Ï¼¾ÅÍ)
Detection of Germline Mutations in Breast Cancer Patients with Clinical Features of Hereditary Cancer Syndrome Using a Multi-Gene Panel Test
½ÅÈñö(¼­¿ïÀÇ´ë)
2 ÀÓ»ó ±è¿ø¼®(»ï¼º¼­¿ïº´¿ø) Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial
±è¼®Áø(»ï¼º¼­¿ïº´¿ø)
3 ÀÓ»ó ·ù¹é·Ä, À¯Ã¢ÈÆ(¼­¿ï¾Æ»êº´¿ø) Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response
°­ÁØÈ£, Á¤ÀçÈ£, ȲÈñ»ó(¼­¿ï¾Æ»êº´¿ø)
4 ÀÓ»ó ½ÉÈ¿¼·(¿¬¼¼ÀÇ´ë) Detection of Targetable Genetic Alterations in Korean Lung Cancer Patients: A Comparison Study of Single-Gene Assays and Targeted Next-Generation Sequencing
¹ÚÀºÇâ(¿¬¼¼ÀÇ´ë)
5 Áß°³ ±è¿­È«(°í·ÁÀÇ´ë) Clinical Implication of Concordant or Discordant Genomic Profiling Between Primary and Matched Metastatic Tissues in Patients with Colorectal Cancer
ÃÖÁ¤À±(°í·ÁÀÇ´ë)
3. Á¦ 11ȸ ¸ÓÅ© ¾ÏÇмú»ó (CRT¿¡ °ÔÀçµÈ ÀÓ»ó³í¹® Áß ´ëÀå¾Ï ¶Ç´Â µÎ°æºÎ ³í¹®, »ó±Ý °¢ 200¸¸¿ø)
No.Ã¥ÀÓÀúÀÚ/ 1ÀúÀÚ³í¹®Á¦¸ñ
1 ±èÅ¿ø(¼­¿ï¾Æ»êº´¿ø) A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair–Deficient/Microsatellite Instability–High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer
±èÁÂÈÆ(¼­¿ï¾Æ»êº´¿ø)
2 ¼Õ´ë°æ(±¹¸³¾Ï¼¾ÅÍ) Magnetic Resonance-Based Texture Analysis Differentiating KRAS Mutation Status in Rectal Cancer
¿ÀÁöÀº(±¹¸³¾Ï¼¾ÅÍ)
3 ¹ÚÀÎÀÚ(¼­¿ï¾Æ»êº´¿ø) Association of Body Composition with Long-Term Survival in Non-metastatic Rectal Cancer Patients
ÇÑÁø¼ö(¼­¿ï¾Æ»êº´¿ø)
4. Á¦ 10ȸ ±¤µ¿¾ÏÇмú»ó
1) ÃÖ°í IF SCI ÇмúÁö¿¡ ³í¹®À» ¹ßÇ¥ÇÑ ±âÃÊ ¹× ÀÓ»ó ºÐ¾ßÀÇ Ã¥ÀÓÀúÀÚ °¢ 1¸í
NoÃ¥ÀÓÀúÀÚ³í¹®Á¦¸ñ°ÔÀçÇмúÁö
1 ÀÌÈ£¿µ(¼­¿ï´ë ¾àÇдëÇÐ) The Interplay between Slow-Cycling, Chemoresistant Cancer Cells and Fibroblasts Creates a Proinflammatory Niche for Tumor Progression Cancer Res.
2020;80(11):2257-2272.
±èÇý·Ã(¿¬¼¼ÀÇ´ë)
2 ÃÖÀÏÁÖ(±¹¸³¾Ï¼¾ÅÍ) Family History of Gastric Cancer and Helicobacter pylori Treatment N Engl J Med.
2020;382(5):427-436.
2) ´Ù¼öÀÇ SCI µîÀç ÇмúÁö¿¡ ³í¹®À» ÀοëÇÏ¿© ³í¹®À» ¹ßÇ¥ÇÑ Ã¥ÀÓ ÀúÀÚ 1¸í
NoÃ¥ÀÓÀúÀÚ³í¹®Á¦¸ñ°ÔÀçÇмúÁö
1 ½Å¾Ö¼±(¼­¿ïÀÇ´ë) Effect of Citric Acid Cycle Genetic Variants and Their Interactions with Obesity, Physical Activity and Energy Intake on the Risk of Colorectal Cancer: Results from a Nested Case-Control Study in the UK Biobank Cancers (Basel).
2020;12(10):2939.
5. Á¦13ȸ ´ëÇѾÏÇÐȸÁö Best Reviewer»ó (4¸í ¼±Á¤, »ó±Ý °¢ 100¸¸¿ø)
:2020³â 1¿ù ~12¿ù±îÁö ½É»çÇÑ À§¿øÀ¸·Î ½É»ç±â°£À» ÁؼöÇÏ°í, ½É»çÀÇ °´°ü¼º, Ÿ´ç¼º, °Ç¼³ÀûÀÎ ÀÇ°ßÀ¸·Î ³í¹®ÀÇ ÁúÀû Çâ»ó¿¡ ±â¿©ÇÑ ½É»çÀ§¿ø ¼±Á¤
¼ö»óÀÚ
Á¤ÇѽŠ(¼º±Õ°üÀÇ´ë À̺ñÀÎÈÄ°ú) ±Ç¼ø¼®(Àü³²ÀÇ´ë ¿¹¹æÀÇÇб³½Ç)
ÀÌ°æÈÆ(¼­¿ïÀÇ´ë ³»°ú) ÀÌÁ¤¿ø(¼­¿ï´ë ¾àÇдëÇÐ)